More HIV Research Highlights from CROI 2017
Topics
New scientific findings from two separate domains were among the key highlights shared during the second day of the 2017 Conference on Retroviruses and Opportunistic InfectionsExit Disclaimer (CROI) in Seattle, according to Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Dr. Dieffenbach and his colleague Anne Rancourt joined us for a Facebook Live session to re-cap some of those findings.
First, new research on our understanding of how the microbiome—the bacteria in our bodies—impacts the potential effectiveness of some forms of pre-exposure prophylaxis for women was presented. They suggested that one formulation of a vaginally applied gel being studied may not be as effective for HIV prevention as hoped when certain bacteria were present in the vaginal microbiome. Second, additional insights were shared at the conference on how antibodies may become possible tools in HIV prevention or treatment. Finally, Carl also responded to a question submitted by a viewer of his highlights video from the previous day about smoking and heart disease among people living with HIV.
To learn about these developments and more, watch their conversation below or on the HIV.gov Facebook pageExit Disclaimer
Over 4,200 HIV researchers have assembled in Seattle this week for the annual CROI conference. The basic, translational, and clinical scientists from 90 countries are sharing and discussing the latest studies, notable developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. Visit the conference websiteExit Disclaimer for abstracts, session descriptions, webcastsExit Disclaimer, and other materials being released over the course of the coming week.
First, new research on our understanding of how the microbiome—the bacteria in our bodies—impacts the potential effectiveness of some forms of pre-exposure prophylaxis for women was presented. They suggested that one formulation of a vaginally applied gel being studied may not be as effective for HIV prevention as hoped when certain bacteria were present in the vaginal microbiome. Second, additional insights were shared at the conference on how antibodies may become possible tools in HIV prevention or treatment. Finally, Carl also responded to a question submitted by a viewer of his highlights video from the previous day about smoking and heart disease among people living with HIV.
To learn about these developments and more, watch their conversation below or on the HIV.gov Facebook pageExit Disclaimer
Over 4,200 HIV researchers have assembled in Seattle this week for the annual CROI conference. The basic, translational, and clinical scientists from 90 countries are sharing and discussing the latest studies, notable developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. Visit the conference websiteExit Disclaimer for abstracts, session descriptions, webcastsExit Disclaimer, and other materials being released over the course of the coming week.